Big Lots Q1 Earnings: Revenue And Profit Miss, Ditches EPS Outlook, Stock Crashes
Big Lots shares plummet as Q1 earnings miss estimates, with net sales declining 10.2% and comparable sales dropping 9.9%.
FDA Selects Moderna’s Rare Disease Candidate For Accelerated Development Program
Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study.
Roaring Kitty’s GameStop Trades Exploit SEC’s Regulatory Gaps, Experts Warn: ‘This Is Obviously Market Manipulation’
The existing rules do not allow the SEC to prosecute this behavior unless deception is involved. Unlike traditional pump-and-dump schemes
What’s Going On With Sagimet Biosciences Stock On Thursday?
Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress.
Ciena Reports Stronger-Than-Expected Q2 Results, CEO Highlights Bandwidth Demand Growth
Ciena reported Q2 2024 revenue of $910.80M, beating analyst estimate of $894.94M. Adjusted EPS of $0.27 beat estimate of $0.15. Total Networking Platforms revenue declined 26.1% while Total Global Services increased 5.4%. Adjusted margins declined. CEO focused on expanding market leadership in optical. Cash and equivalents of $1.42B.
BYD, A Tesla Rival, Maintains Second Spot In EV Battery Makers Market: Report
BYD Co., Ltd. maintains its position as the world's second-largest EV battery manufacturer from January to April.
Why Software Company Sprinklr Shares Are Diving Today
Sprinklr reported lower Q1 FY25 results, with sales of $196.0M and adjusted EPS of $0.09 beating consensus. Co-CEO appointed and share buyback announced.
J.M. Smucker’s Bottom-Line Shines In Q4 As Cost Management Pays Off: Details
J.M. Smucker shares rise as Q4 FY24 earnings report shows a gross profit surge of 15% Y/Y to $913.3 million and an expanded gross profit margin of 41.4%. Despite a 1.3% sales decline to $2.21 billion, adjusted EPS of $2.66 beat estimates.
Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September
The company also mentioned that it anticipates commercial delivery of the protein-based vaccine in the U.S. in September, pending authorization. The
Vista Outdoor Surges As MNC Capital Ups The Ante With Sweetened Bid: Details
Vista Outdoor Inc. shares rise as MNC Capital raises offer to over $3.0 billion. The revised offer is over a 30% premium to the last closing price before MNC's initial offer.